Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P53634

UPID:
CATC_HUMAN

ALTERNATIVE NAMES:
Cathepsin C; Cathepsin J; Dipeptidyl peptidase I; Dipeptidyl transferase

ALTERNATIVE UPACC:
P53634; A8K7V2; B5MDD5; Q2HIY8; Q53G93; Q71E75; Q71E76; Q7M4N9; Q7Z3G7; Q7Z5U7; Q8WY99; Q8WYA7; Q8WYA8

BACKGROUND:
Dipeptidyl peptidase 1, with alternative names such as Cathepsin C and Dipeptidyl peptidase I, is a thiol protease with significant implications in human health. Its enzymatic activity, capable of acting on a wide array of dipeptide substrates, plays a pivotal role in activating key serine proteases involved in immune defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Given its association with genetic disorders like Papillon-Lefevre syndrome and aggressive periodontitis, Dipeptidyl peptidase 1 represents a promising target for drug discovery efforts. The protein's link to these diseases, through variants affecting its gene, suggests that targeting its activity could lead to breakthrough treatments for patients suffering from these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.